Amity Institute of Microbial Technology, Amity University Rajasthan, Jaipur, 303002, India.
Kusuma School of Biological Sciences, India Institute of Technology Delhi, New Delhi, 110016, India.
Appl Biochem Biotechnol. 2023 Sep;195(9):5568-5582. doi: 10.1007/s12010-022-03950-4. Epub 2022 Jun 6.
Urinary tract infections (UTIs) are among the most prevalent bacterial infections worldwide, with 11% of the global population getting infected every year. These infections are largely attributed to quorum sensing (QS)-dependent ability of pathogens to form biofilms in the urinary tract. Antimicrobial resistance is increasing, and the use of antimicrobial medicines in the future is yet uncertain. The desert medicinal plants have great potential to treat several diseases as per the available ethnobotanical database. Some of these plants have been used in folklore medicines to treat urinary tract infections also. There are many bioactive compounds derived from these desert medicinal plants that have been documented to possess antimicrobial as well as antibiofilm activity against uropathogens. The minimum biofilm inhibitory concentration (MBIC) of these plant extracts have been reported in the range of 31.5-250 μg/mL. The rising prevalence of drug-resistant diseases necessitates standardised modern analytical technologies to detect and isolate novel bioactive compounds from medicinal plants. This review seeks to combine the studies of desert plants with antimicrobial and anti-quorum sensing properties, supporting their sustainable use in treatment of urinary tract infections.
尿路感染（UTIs）是全球最普遍的细菌性感染之一，每年有 11%的全球人口受到感染。这些感染主要归因于病原体通过群体感应（QS）在尿路中形成生物膜的能力。抗菌素耐药性正在增加，未来抗菌素药物的使用尚不确定。根据现有的民族植物学数据库，沙漠药用植物具有治疗多种疾病的巨大潜力。这些植物中的一些已被用于民间医学来治疗尿路感染。已经有许多从这些沙漠药用植物中提取的生物活性化合物被证明具有抗微生物和抗生物膜活性，可对抗尿路病原体。这些植物提取物的最低生物膜抑制浓度（MBIC）已报道在 31.5-250 μg/mL 的范围内。耐药性疾病的流行率上升需要标准化的现代分析技术来从药用植物中检测和分离新型生物活性化合物。本综述旨在将具有抗微生物和抗群体感应特性的沙漠植物研究结合起来，支持它们在治疗尿路感染方面的可持续使用。
